Literature DB >> 22901466

Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.

Penny Nymark1, Mervi Aavikko, Jussi Mäkilä, Salla Ruosaari, Tuija Hienonen-Kempas, Harriet Wikman, Kaisa Salmenkivi, Risto Pirinen, Antti Karjalainen, Esa Vanhala, Eeva Kuosma, Sisko Anttila, Eeva Kettunen.   

Abstract

We have previously demonstrated an association between genomic alterations in 19p13, 2p16, and 9q33.1 and asbestos exposure in patients' lung tumours. This study detected allelic imbalance (AI) in these regions in asbestos-exposed lung cancer (LC) patients' histologically normal pulmonary epithelium. We extended the analyses of tumour tissue to cover a large LC patient cohort and studied DNA copy number alteration (CNA) and AI in 19p13, 2p16, and 9q33.1 for the first time in combination. We found both CNA and AI in ≥2/3 of the regions to be significantly and dose-dependently (P < 0.001) associated with pulmonary asbestos fibre count. Twenty percent of the exposed patients' LC showed CNA in ≥2/3 of the regions, whereas none of the non-exposed patients' LC showed CNA in more than one region. AI was evident in 89% of the exposed and in only 26% of the non-exposed patients' LC. The genomic alterations in 19p13, 2p16, and 9q33.1 in compilation identified asbestos-exposed patients' lung tumours better than each of the regions alone. These alterations form the basis for the development of a combinatorial molecular assay that could be used to identify asbestos-related LC.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901466      PMCID: PMC5528398          DOI: 10.1016/j.molonc.2012.07.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  43 in total

1.  Improved procedure for fluorescence in situ hybridization on tissue microarrays.

Authors:  C L Andersen; G Hostetter; A Grigoryan; G Sauter; A Kallioniemi
Journal:  Cytometry       Date:  2001-10-01

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer.

Authors:  Kim S Kraunz; Heather H Nelson; Miriam Lemos; John J Godleski; John K Wiencke; Karl T Kelsey
Journal:  Int J Cancer       Date:  2006-03-15       Impact factor: 7.396

4.  3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy.

Authors:  J Sanz-Ortega; M C Saez; E Sierra; A Torres; J L Balibrea; F Hernando; J Sanz-Esponera; M J Merino
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

5.  Identification of specific gene copy number changes in asbestos-related lung cancer.

Authors:  Penny Nymark; Harriet Wikman; Salla Ruosaari; Jaakko Hollmén; Esa Vanhala; Antti Karjalainen; Sisko Anttila; Sakari Knuutila
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH.

Authors:  P M Lindholm; K Salmenkivi; H Vauhkonen; A G Nicholson; S Anttila; V L Kinnula; S Knuutila
Journal:  Cytogenet Genome Res       Date:  2007-12-14       Impact factor: 1.636

7.  UHRF1 is a novel diagnostic marker of lung cancer.

Authors:  M Unoki; Y Daigo; J Koinuma; E Tsuchiya; R Hamamoto; Y Nakamura
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

8.  DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure.

Authors:  E Kettunen; M Aavikko; P Nymark; S Ruosaari; H Wikman; E Vanhala; K Salmenkivi; R Pirinen; A Karjalainen; E Kuosma; S Anttila
Journal:  Br J Cancer       Date:  2009-03-31       Impact factor: 7.640

9.  Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients.

Authors:  Salla Ruosaari; Tuija Hienonen-Kempas; Anne Puustinen; Virinder K Sarhadi; Jaakko Hollmén; Sakari Knuutila; Juha Saharinen; Harriet Wikman; Sisko Anttila
Journal:  BMC Med Genomics       Date:  2008-11-11       Impact factor: 3.063

10.  The asbestos cancer epidemic.

Authors:  Joseph LaDou
Journal:  Environ Health Perspect       Date:  2004-03       Impact factor: 9.031

View more
  6 in total

1.  Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.

Authors:  Satu Mäki-Nevala; Virinder Kaur Sarhadi; Aija Knuuttila; Ilari Scheinin; Pekka Ellonen; Sonja Lagström; Mikko Rönty; Eeva Kettunen; Kirsti Husgafvel-Pursiainen; Henrik Wolff; Sakari Knuutila
Journal:  Lung       Date:  2016-02       Impact factor: 2.584

Review 2.  Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.

Authors:  Giovanni Brandi; Kurt Straif; Daniele Mandrioli; Stefania Curti; Stefano Mattioli; Simona Tavolari
Journal:  Ann Glob Health       Date:  2022-06-13       Impact factor: 3.640

3.  CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.

Authors:  Eeva Kettunen; Sauli Savukoski; Kaisa Salmenkivi; Tom Böhling; Esa Vanhala; Eeva Kuosma; Sisko Anttila; Henrik Wolff
Journal:  BMC Cancer       Date:  2019-05-28       Impact factor: 4.430

Review 4.  Asbestos and Intrahepatic Cholangiocarcinoma.

Authors:  Giovanni Brandi; Simona Tavolari
Journal:  Cells       Date:  2020-02-12       Impact factor: 6.600

Review 5.  The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer.

Authors:  Yuen Yee Cheng; Emma M Rath; Anthony Linton; Man Lee Yuen; Ken Takahashi; Kenneth Lee
Journal:  Lung Cancer (Auckl)       Date:  2020-01-08

6.  Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.

Authors:  Tomoaki Naka; Yutaka Hatanaka; Katsuji Marukawa; Hiromi Okada; Kanako C Hatanaka; Jun Sakakibara-Konishi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Tomoko Mitsuhashi; Yoshihiro Matsuno
Journal:  Diagn Pathol       Date:  2016-04-18       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.